Sponsored by:

Business in the Burbs

Movers, shakers and newsmakers

Regeneron receives $20 million after patient enrolled in study


Regeneron Pharmaceuticals Inc., a biotech company based in Eastview, said that it has received a $20 million payment after enrolling the first patient in a study that looks at the effectiveness of its its VEGF Trap-Eye as a potential treatment for central retinal vein occlusion, a leading cause of blindness.

Regeneron received the payment as part of an agreement with Bayer HealthCare AG, its partner in developing VEGF Trap-Eye as a treatment for various eye diseases. The latest testing program includes patients from multiple countries participating in two one-year studies.

This entry was posted on Thursday, July 23rd, 2009 at 4:09 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical



About this blog
Business in the Burbs is our online news blog about businesses based or operating in the Lower Hudson Valley. Visitors here will also find items of interest to consumers in the region. Most contributions are from business reporters and editors covering Westchester, Rockland and Putnam counties.


Get blog updates via email:

About the Authors


Other recent entries


Monthly Archives